Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort

Click to increase image sizeClick to decrease image size

Disclosure

Dr T Greulich reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL-Behring, GlaxoSmithKline, Grifols, MedUpdate, Mundipharma, and Novartis. S Mager and Dr T Lucke report no conflicts of interest. Professor Dr AR Koczulla reports grants from Boehringer-Ingelheim, Astra Zeneca, Novartis, Grifols, CSCSL, Roche, Teva, Berlin-Chemie, Chiesi und Novotec, outside the submitted work. Professor Dr R Bals reports grants from BMBF, AstraZeneca GmbH, Bayer Schering Pharma AG, Boehringer Ingelheim Pharma GmbH & Co. KG, Chiesi GmbH, GlaxoSmithKline, Grifols Deutschland GmbH, MSD Sharp & Dohme GmbH, Mundipharma GmbH, Novartis Deutschland GmbH, Pfizer Pharma GmbH, Takeda Pharma Vertrieb GmbH & Co. KG., during the conduct of the study; as well as grants from Wilhelm-Sander-Stiftung, grants from Deutsche Krebshilfe and grants from Schwiete-Stiftungoutside the submitted work. Dr S Fähndrich reports grants from Grifols, CSL Behring, and AstraZeneca, outside the submitted work. Dr RA Jörres reports grants from Federal Ministry of Education and Research (grant number 01GI0881, 01GI0882), during the conduct of the study. Professor Dr P Alter reports grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), grants from AstraZeneca GmbH, grants and non-financial support from Bayer Schering Pharma AG, grants, personal fees and non-financial support from Boehringer Ingelheim Pharma GmbH & Co. KG, grants and non-financial support from Chiesi GmbH, grants from GlaxoSmithKline, grants from Grifols Deutschland GmbH, grants from MSD Sharp & Dohme GmbH, grants and personal fees from Mundipharma GmbH, grants, personal fees and non-financial support from Novartis Deutschland GmbH, grants from Pfizer Pharma GmbH, grants from Takeda Pharma Vertrieb GmbH & Co. KG, outside the submitted work. Dr AM Kirsten reports personal fees from Astra Zeneca and Boehringer Ingelheim, outside the submitted work. Professor Dr CF Vogelmeier reports grants from AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Grifols, Menarini, Mundipharma, Novartis, Teva, Cipla, Omniamed, and MedUpdate. Dr H Watz reports personal fees from AstraZeneca, personal fees from Takeda, personal fees from BerlinChemie, personal fees from BoehringerIngelheim, personal fees from Chiesi, personal fees from Novartis, personal fees from GlaxoSmithKline, personal fees from Roche, outside the submitted work. The authors report no other conflicts of interest in this work.